Delayed cancer diagnosis and treatment is the next health crisis facing Latin America. The global pandemic interrupted the diagnosis-to-treatment pathway, increasing both mortality rates and treatments costs for later-stage diseases. The only way to reverse these trends is to create a surge in diagnostic and treatment bandwidth.
To drive awareness, MSD commissioned FrontierView to analyze publicly available data in Latin America around this issue. FrontierView quantified the number of missed preventive screenings during the pandemic, as well as the gap between current screening levels and targeted screening coverage of eligible populations for cervical and breast cancer in Brazil, Mexico, and Peru, where good public data is available.
During the webinar, we’ll present our study’s findings and explore how we can enhance screening programs’ capacity and precision to increase the number of diagnoses and improve the patient journey.
Jordana Lück Wagner, Consulting Director – FrontierView
Diego F Guarin MD MPH MSc, Executive Director, Regional Market Access Latin America – Merck (MSD)
Alec Lee, Healthcare Research Director – FrontierView
Camila de Pamphilis, Chief Data & Patient Experience Officer – Mamotest